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Abstract 46 
Objective: After the initial report of a CHCHD10 mutation in mitochondrial disease 47 
with features resembling amyotrophic lateral sclerosis (ALS), CHCHD10 mutations 48 
have been considered to be a frequent cause for ALS. The exact pathogenicity and 49 
clinical significance, however, of these mutations remain unclear. Here, we aimed to 50 
determine the role of CHCHD10 mutations in ALS. 51 
Methods: We included 4,365 whole genome sequenced ALS patients and 1,832 52 
controls from 7 different countries and examined all non-synonymous single 53 
nucleotide variants (SNVs) in CHCHD10. These were tested for association with 54 
ALS, independently and in aggregate using several genetic burden tests (including 55 
SKAT and SKAT-O). 56 
Results: We identified three new variants in cases, but only one was case-specific. 57 
Also, one control-specific mutation was identified. There was no increased burden of 58 
rare coding mutations among ALS patients compared to controls (P = 0.88 and P = 59 
1.00 for SKAT and SKAT-O, respectively). The few carriers with potential 60 
pathogenic CHCHD10 mutations exhibited a slowly progressive ALS-like phenotype 61 
with atypical features such as myopathy and deafness. 62 
Interpretation: CHCHD10 mutations seem to be a far less prevalent cause of pure 63 
ALS than previously suggested, but instead appear related to more complex 64 
phenotypes. There appears to be insufficient evidence for the pathogenicity of most 65 
previously reported variants in pure ALS. This study shows that routine testing for 66 
CHCHD10 mutations in pure ALS is not recommended and illustrates the importance 67 
of sufficient genetic and functional evidence in establishing pathogenicity of genetic 68 
variants. 69 
Abbreviations 70 
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Amyotrophic lateral sclerosis (ALS); Frontotemperal dementia (FTD); minor allele 71 
frequency (MAF); Sequence kernel association test (SKAT); single nucleotide variant 72 
(SNV);  73 
 74 
Introduction 75 
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurological disease 76 
characterized by the degeneration of both upper and lower motor neurons, leading to 77 
progressive muscle weakness and respiratory failure.1 Using next-generation 78 
sequencing, mutations in several genes have been reported, especially in the 79 
minority of cases with a positive family history of ALS.2 These discoveries have not 80 
only led to increased understanding of the pathophysiology of ALS and the possible 81 
development of specific therapeutic agents, but also play an important role in genetic 82 
counselling.  83 
CHCHD10 was proposed as a new candidate gene for ALS, after a novel 84 
mutation in CHCHD10 was described as co-segregating with a complex variable 85 
phenotype, including cognitive decline resembling frontotemporal dementia (FTD), 86 
cerebellar ataxia, myopathy, sensorineural deafness and an ALS-like motor neuron 87 
disease.3 Although subsequent screening in different populations has led to the 88 
description of over 20 mutations in CHCHD10 in ALS and other neurodegenerative 89 
diseases (most of which are located in exon 2)4-7, our certainty in the causality of 90 
these variants for ALS remains an open question.8, 9  91 
Typically, to establish the causality of the identified CHCHD10 variants, 92 
investigators used functional effect predictors for individual mutations and (virtual) 93 
absence in public databases. However, it is widely accepted that these criteria alone 94 
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are insufficient proof of causality for low frequency variants8, especially if those 95 
variants were identified in single families but never followed up in additional samples. 96 
Consequently, these lenient criteria for claiming causality between a variant and 97 
disease might lead to false positive reports due to a combination of factors: 98 
incomplete penetrance, lack of adequate coverage in exome-captured data, rare 99 
genetic variation that may be geographically specific, or simply no relationship 100 
between the variant and disease (discoverable through investigation of increased 101 
sample sizes).10, 11 Nevertheless, influential online resources and literature for 102 
genetic counseling have already adopted CHCHD10 variation as causal for ALS and 103 
suggest genetic testing in the clinic (http://neuromuscular.wustl.edu/).12 104 
To determine the clinical impact and importance of genetic testing for claimed 105 
CHCHD10 variants in ALS, we have set out to investigate the true genetic 106 
contribution of CHCHD10 variants in a large international cohort of whole genome 107 
sequenced ALS patients and controls. 108 
 109 
Materials and Methods 110 
Sample collection 111 
DNA was isolated from whole blood samples collected from 4,853 ALS patients from 112 
7 different populations (Belgium, Ireland, The Netherlands, The United Kingdom, The 113 
United States of America, Spain and Turkey) and 1,991 controls matched for age, 114 
geographical location and sex. All patients and control subjects provided written 115 
informed consent and the relevant institutional review boards approved this study. 116 
Sequencing and analysis 117 
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DNA samples were sequenced using PCR-free library preparation and paired-end 118 
sequencing on the HiSeq 2000 (100 bp) and HiSeq X platform (150 bp) (Illumina®, 119 
San Diego, USA). Reads were aligned to the hg19 human genome build using the 120 
Isaac alignment software and the Isaac variant caller was used to call and filter 121 
single nucleotide variants using standard quality control (QC) parameters.13 122 
Additional QC removed duplicated or poorly called individuals (genotype 123 
missingness > 5%, Ti/Tv > 2.092, het/hom ratio > 3.1) and genomic sites (high or low 124 
depth of coverage, aggregated passing rate < 0.7 across the sample, missingness > 125 
5%, HWE p < 1 x 10-6). We also removed all closely related (kinship coefficient > 126 
0.0625) and sex-check failing samples based on comparison of phenotype and 127 
sequencing data.14 The genomic region of CHCHD10 (NCBI Reference Sequence: 128 
NG_034223.1) was isolated from the VCFs and variants were annotated using 129 
Variant Effect Predicitor.15 130 
Burden Testing 131 
Gene regions were isolated based on their canonical transcripts in the Ensembl 132 
database (http://www.ensembl.org). Within these regions, single nucleotide variants 133 
(SNVs) that were annotated as missense or loss-of-function mutations with a minor 134 
allele frequency (MAF) <1% in the control population and public databases were 135 
selected for burden testing. Burden testing on cases and controls was performed 136 
using bidirectional sequence kernel association test (SKAT) together with SKAT-O to 137 
account for an unidirectional effect, more likely in the case of mainly damaging 138 
variants.16 Association tests were corrected for population stratification using the first 139 
10 principal components. Additionally, 100.000 permutations were performed with 140 
SKAT-O to obtain the empirical SKAT-O p-value. Statistical analyses were carried 141 
out using R software (http://www.r-project.org). 142 
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 143 
Results 144 
To investigate variants in CHCHD10, we analyzed all rare, non-synonymous SNVs in 145 
the whole-genome sequencing data of 4,365 ALS (± FTD) samples together with 146 
1,832 unaffected controls. We identified seven SNVs in ALS cases, three of which 147 
were not previously reported (Table 1). Screening of controls revealed that only three 148 
out of these seven variants were case-specific, as the other four variants were also 149 
found in controls. Additionally, one control-specific SNV was identified. 150 
 151 
No increased burden of rare variants 152 
Neither the SKAT nor the SKAT-O association tests showed a significant increased 153 
burden of rare non-synonymous variants in CHCHD10 among ALS patients (P = 154 
0.88 and P = 1.00, respectively; Table 2). As a positive control, we tested three other 155 
genes (SOD1, FUS and TARDBP), which are known to harbor rare pathogenic SNVs 156 
in ALS.17 These genes did yield a significant SKAT-O association statistic (P = 157 
0.008, P = 0.02, and P = 0.03 respectively; Table 2). 158 
 159 
Additional clinical information on carriers  160 
Only three rare missense mutations in CHCHD10 were specific to ALS cases (Table 161 
2). The previously unreported p.Arg11Gly mutation was identified in a single female 162 
ALS case from the United States without cognitive involvement and a negative family 163 
history for ALS or dementia.  We identified three cases with the previously reported 164 
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p.Arg15Leu variant: one Dutch and two American cases, one of which was already 165 
included in the previous study by Johnson et al. (ND11809).5 Although both 166 
American cases had a positive family history, the additional Dutch ALS patient did 167 
not have a family history of ALS or dementia. Similar to previously described 168 
carriers, the clinical phenotype in this patient was characterized by very slow 169 
progression with both upper and lower motor neuron involvement, a long diagnostic 170 
delay of two years and a disease duration of over eight years after onset.5, 6, 18 171 
Interestingly, besides motor neuron disease, this patient presented with an atypical 172 
phenotype including deafness, weakness of the proximal upper extremities and low 173 
tendon reflexes. Unfortunately, no muscle biopsies were performed. The third case-174 
specific mutation (p.Pro80Leu), previously reported in an Italian ALS patient with an 175 
abnormal muscle biopsy (COX deficiency), was found in a Belgian ALS patient.7 This 176 
patient also presented with an atypical myopathy-like clinical phenotype with 177 
proximal lower limb weakness and high serum creatine kinase levels (up to 1800 178 
U/l). The clinical features at the time of presentation prompted the neurologist to 179 
request a muscle biopsy, which showed neurogenic atrophy, but without 180 
histochemical analysis for COX. 181 
 182 
Discussion 183 
CHCHD10 was proposed to be a new candidate gene for ALS following the initial 184 
report of a p.Ser59Leu variant, which was detected in a family with a complex 185 
phenotype including ataxia, myopathy, dementia and a progressive motor neuron 186 
disease resembling ALS.3 Subsequently, several studies screened for CHCHD10 187 
mutations in ALS patients and healthy controls and claimed pathogenicity for multiple 188 
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rare missense variants.4-6 In this study, we used whole-genome sequencing data on 189 
a large international cohort of ALS patients to investigate the frequency of CHCHD10 190 
variants and evaluated the genetic evidence for their pathogenicity.  191 
In our cohort of 4,365 ALS patients and 1,832 controls, we only detected three 192 
rare, case-specific, missense variants, two of which have been previously reported. 193 
The only remaining novel ALS-specific variant, a heterozygous c.31C>G variant 194 
resulting in a p.Arg11Gly amino acid change, was found in a single ALS case and is 195 
therefore of unknown significance. Furthermore, we also identified a rare missense 196 
variant (p.Ala72Val) in a single control sample, indicating that unique coding variants 197 
can be found in controls as well. Together with our data, there are now 13 reported 198 
rare nonsynonymous variants in CHCHD10 in pure ALS, most of which are 199 
concentrated in exon 2 (Figure 1). Missense mutations in exon 2 were also detected 200 
in other neurodegenerative diseases, some of which closely related to ALS. Although 201 
this might hint towards pleiotropy, it is important to realize that most reported variants 202 
were unique to a single case or family and that this exon is only moderately covered 203 
in whole-exome sequencing-based public databases such as ExAC, making it prone 204 
to false positive reports.10 205 
In order to interpret the collection of rare variants in cases and/or controls, we 206 
tested whether there is an increased burden of rare non-synonymous variants in 207 
CHCHD10 among ALS patients. The results of the SKAT and SKAT-O association 208 
tests show no significant association between rare coding variants in CHCHD10 and 209 
ALS, whereas genes which are known for causative rare variants in ALS did show a 210 
significant association of non-synonymous variants in ALS in SKAT-O only (which 211 
was expected as variants in these genes are known to be damaging, not protective).  212 
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In the absence of linkage or a statistically significant burden test, all variants 213 
that are solely observed in a single case do not meet criteria for pathogenicity.8 Only 214 
variants that occur in multiple unrelated cases (and no controls) are potentially more 215 
interesting. Together with previous reports, only six CHCHD10 variants have met this 216 
criterion (Table 4). Some of these variants are already listed as pathogenic in public 217 
databases such as ClinVar (https://www.ncbi.nlm.nih.gov/clinvar) despite the fact 218 
that other criteria for establishing pathogenicity were often not investigated.  219 
So far, the most convincing evidence for CHCHD10 pathogenicity was 220 
provided for the p.Ser59Leu variant, using both clinical and genetic data on multiple 221 
affected and unaffected family members. The clinical phenotype described in these 222 
carriers, however, is not pure ALS and includes atypical features such as deafness, 223 
myopathy, cerebellar ataxia and Parkinsonism.3 With our focus on typical ALS, we 224 
will critically appraise the genetic evidence for the five other reported variants.  225 
Similar to previous observations, the most frequent rare non-synonymous 226 
SNV in our dataset was the heterozygous p.Pro34Ser, which was present in 37 227 
cases (0.85%) as well as 15 control samples (0.82%) (corrected F2(1) = 0.00  P = 228 
0.98). Despite initial reports of possible pathogenicity of this variant in pure ALS േ 229 
FTD, our data adds to the increasing evidence that the p.Pro34Ser mutation in 230 
CHCHD10 is probably not pathogenic.19-22 Recent in vitro studies still support 231 
p.Pro34Ser pathogenicity as similar cellular pathology between CHCHD10S59L and 232 
CHCHD10P34S mutant cell lines was shown.23 Despite the in vitro findings, the fact 233 
that the p.Pro34Ser variant is as common in ALS patients as in the general 234 
population, indicates that a HeLa cellular phenotype alone does not justify classifying 235 
 10 
the p.Pro34Ser variant as an ALS causing mutation and could merely indicate the 236 
limitation of these models to represent human ALS-pathology.  237 
Previous screening of a subset of sporadic ALS patients with COX-deficient 238 
muscle biopsies led to the discovery of a c.244C>T substitution (p.Pro80Leu) in exon 239 
2, which was subsequently reported in two sporadic and one familial ALS cases in 240 
Italy and Canada.7, 24 We have identified an additional sporadic case in our Belgian 241 
cohort with a similar atypical phenotype. However, the allele frequency of this variant 242 
in ALS cases after exclusion of possibly overlapping cohorts (5/12700 = 0.0004) is 243 
almost identical to the general population in the ExAC database (32/92470 = 0.0003, 244 
corrected F2(1) = 0.00 P = 0.99). Moreover, the frequency in the ExAC database 245 
might even be an underestimation as exon 2 is only moderately represented (Figure 246 
1).  247 
The fourth and fifth variants which were identified in multiple ALS cases are 248 
the p.Pro96Thr and p.Tyr135His mutations. These variants are located in exon 3 249 
and, similar to p.Pro80Leu, pathogenicity is unlikely due to similar allele frequencies 250 
in control samples.20, 25-27 Notably, the p.Pro96Thr is the only variant which was 251 
found to be homozygous (in 3 out of 5 cases). Given its high frequency in the African 252 
population in ExAC (692/2704 = 0.2559) however, a pathogenic recessive nature of 253 
this mutation seems highly unlikely.  254 
The last variant, c.44G>T (p.Arg15Leu), was previously detected in six 255 
families with ALS and one sporadic ALS case.5, 6, 18, 28 This variant is probably of the 256 
most interest in ALS as it was identified in multiple cohorts, with absence in any of 257 
the screened controls, and segregates with disease in familial cases (although there 258 
were three unaffected carriers in one of the families, possibly due to incomplete 259 
 11 
penetrance).6 Here, we report two new carriers: one in the Dutch cohort and one in 260 
the US cohort (the other US carrier has already been reported). Although limited, the 261 
available clinical data for these patients seems to be similar to that reported in other 262 
carriers (predominant lower-motor neuron symptoms and slow disease progression) 263 
with some atypical symptoms in one patient (bilateral hearing loss and proximal 264 
onset).6, 18 This again points towards a distinct ALS-like clinical phenotype. However, 265 
the percentage of ALS cases which might be explained due to this variant is 0.1% 266 
(9/6,797 non-overlapping cases) making it a possibly pathogenic but very rare 267 
CHCHD10 variant in motor-neuron disease. 268 
The association of CHCHD10 mutations in motor-neuron disease resembling 269 
ALS is further illustrated by the c.197G>T (p.Gly66Val) variant, which was originally 270 
described in a Finnish familial ALS patient with slowly ascending progressive motor 271 
neuron disease. This variant was later shown to cause a lower motor neuron 272 
phenotype without upper-motor neuron or cognitive involvement as it was identified 273 
in 75 Finnish carriers with hereditary, late onset spinal motor neuropathy (SMAJ), 274 
Charcot-Marie Tooth disease Type 2 or both.6, 29-31  275 
Overall, there seems to be potential evidence for the involvement of 276 
CHCHD10 in neurodegenerative diseases, particularly in combination with clinical 277 
features that suggest mitochondrial dysfunction, such as myopathy or hearing-loss. 278 
In the case of pure ALS however, our results indicate that rare genetic variants in 279 
CHCHD10 can be detected in both cases and controls at similar frequencies. 280 
Therefore, CHCHD10 variants seem to be a far less prevalent cause of pure ALS 281 
than previously suggested.5 This study shows that routine testing for 282 
CHCHD10 variants in pure ALS is not recommended and illustrates the importance 283 
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of sufficient genetic and functional evidence in establishing pathogenicity of genetic 284 
variants. 285 
286 
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Table 1. CHCHD10 Variants in Project Mine Overview of rare (MAF <1%) single 337 
nucleotide variants, functionally annotated as missense of loss of function in a total 338 
of 4,365 ALS and 1,832 control samples with the genomic location, location in 339 
transcript NM_213720.1 and predicted amino acid change, allele counts and 340 
corresponding minor allele frequencies (MAF) together with the MAF of the 341 
European population in the ExAC database. 342 
343 
Genome Transcript Consequence 
Alleles 
Cases 
Alleles 
Controls 
MAF  
Cases 
MAF 
Controls 
 
MAF 
ExAC 
22:24108321 A>G c.403T>C p.Tyr135His 3 1 0.00034 0.00027 
 
0.00030 
22:24109583 G>A c.239C>T  p.Pro80Leu 1 0 0.00011 - 
 
0.00047 
22:24109598 C>G c.234G>C p.Gly75Ala 1 1 0.00011 0.00027 
 
0.00002 
22:24109607 G>A c.225C>T p.Ala72Val 0 1 - 0.00027 
 
0.00005 
22:24109722 G>A c.100C>T p.Pro34Ser 37 15 0.00423 0.00409 0.00298 
22:24109778 C>A c.44G>T p.Arg15Leu 3 0 0.00034 - 
 
- 
22:24110031 G>C c.31C>G p.Arg11Gly 1 0 0.00011 - 
 
- 
22:24110046 G>C c.16C>G p.Arg6Gly 1 2 0.00011 0.00055 
 
0.00007 
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 344 
 345 
Gene nvar 
SKAT  
p-value 
SKAT-O 
p-value 
permuted 
SKAT-O 
CHCHD10 8 0.8773 1 1 
SOD1 27 0.3063 0.0006 0.0008 
FUS 22 0.6156 0.0245 0.0242 
TARDBP 19 0.6167 0.0283 0.0300 
 346 
 347 
Table 2. Burden Testing Results of burden test analysis using SKAT and SKAT-O 348 
association testing on rare (MAF<1%) non-synonymous single nucleotide variants in 349 
CHCHD10 and known ALS genes. Nvar indicates the number of SNVs which were 350 
taken into account for association testing. 351 
352 
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  353 
 354 
Mutation Cohort Sex AAO 
(yr) 
Surv 
(mo) 
SOO Myopathy Muscle 
Biopsy 
Deafness Ataxia Sensory 
deficits 
FTD Family 
History 
p.Pro80Leu BE M 61 54 LE Yes Yes No No No No No 
p.Arg15Leu NL M 73 76 UE Possible No Yes No No No No 
p.Arg15Leu US F 42 - LE - - - No No No ALS 
p.Arg15Leu US F 71 - LE - - - No No No ALS 
p.Arg11Gly US F 47 64 LE - - - 
 
No No No Myasthenia 
 355 
 356 
Table 3. Clinical information on carriers of observed ALS specific missense 357 
variants. Overview of known clinical data available for carriers of ALS-specific rare 358 
CHCHD10 missense mutations in our study; Country of sample origin (Cohort)(BE = 359 
Belgium, NL = The Netherlands, US = The United States of America), Age of onset 360 
in years (AAO), Survival after onset in months (Surv) Site of onset (SOO) (LE = 361 
lower extremities, UE = upper extremities), Clinical indications for Myopathy 362 
(Myopathy). 363 
364 
 18 
  365 
 366 
 
Project Mine Previous reports   
Variants: 
ALS Controls ALS Controls Segregation in 
Pedigree(s): 
ClinVar 
p.Arg15Leu 
3 0 7 0 Yes Conflicting 
 
p.Pro34Ser 
37 15 20 25 No* Pathogenic 
 
p.Ser59Leu 0 0 2 0 Yes Pathogenic 
p.Pro80Leu  
1 0 4 0 Unknown Pathogenic 
 
p.Pro96Thr** 2 2 6 3 Unknown Unknown 
p.Tyr135His 3 1 1 0 Unknown Unknown 
Total screened 
8730 3664 7560 6604   
No overlap 
5140 2778   
  
 
* In a pedigree with FTD22 
**Allele counts were not provided in all reports25 
 367 
Table 4. Non-synonymous CHCHD10 variants in multiple ALS / FTD cases. 368 
Overview of total number of alleles and variant alleles, evidence of segregation in 369 
pedigrees and reported clinical significance in ClinVar database of variants that were 370 
previously and currently reported in multiple (>1) seemingly unrelated ALS or FTD 371 
patients. Alleles that were present in affected or unaffected family members were 372 
excluded. No overlap indicates the minimum number of alleles that were screened in 373 
non-overlapping cohorts (after removal of UK, US and SP cohorts). 374 
375 
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  376 
 377 
Figure 1. Non-synonymous CHCHD10 variants in neurodegenerative diseases. 378 
Overview of rare non-synonymous variants in ALS and other neurodegenerative 379 
diseases and their exonic location in CHCHD10. The top panel shows depth of 380 
coverage of CHCHD10 in the ExAC public database (orange) and Project Mine 381 
whole-genome sequencing data (blue-grey) (http://databrowser.projectmine.com). 382 
The grey panel shows all variants reported in pure ALS r FTD; variants in green 383 
were present in multiple seemingly unrelated cases and absent in controls, orange 384 
variants were identified in both cases as well as controls and red variants were found 385 
in a single ALS case. The light grey panel shows variants reported in a more 386 
extensive phenotype that includes motor neuron disease. The bottom panel shows 387 
all variants and their location that were reported in other neurodegenerative diseases 388 
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motor neuronopathy, CMT2 = Charcot-Marie Tooth Type 2). 390 
391 
 21 
References 392 
1. Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of 393 
amyotrophic lateral sclerosis. Nat Rev Neurol. 2011 Oct 11;7(11):639-49. 394 
2. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: what 395 
do we really know? Nat Rev Neurol. 2011 Oct 11;7(11):603-15. 396 
3. Bannwarth S, Ait-El-Mkadem S, Chaussenot A, et al. A mitochondrial origin for 397 
frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. 398 
Brain. 2014 Aug;137(Pt 8):2329-45. 399 
4. Chaussenot A, Le Ber I, Ait-El-Mkadem S, et al. Screening of CHCHD10 in a French 400 
cohort confirms the involvement of this gene in frontotemporal dementia with amyotrophic 401 
lateral sclerosis patients. Neurobiol Aging. 2014 Dec;35(12):2884 e1-4. 402 
5. Johnson JO, Glynn SM, Gibbs JR, et al. Mutations in the CHCHD10 gene are a 403 
common cause of familial amyotrophic lateral sclerosis. Brain. 2014 Dec;137(Pt 12):e311. 404 
6. Muller K, Andersen PM, Hubers A, et al. Two novel mutations in conserved codons 405 
indicate that CHCHD10 is a gene associated with motor neuron disease. Brain. 2014 406 
Dec;137(Pt 12):e309. 407 
7. Ronchi D, Riboldi G, Del Bo R, et al. CHCHD10 mutations in Italian patients with 408 
sporadic amyotrophic lateral sclerosis. Brain. 2015 Aug;138(Pt 8):e372. 409 
8. MacArthur DG, Manolio TA, Dimmock DP, et al. Guidelines for investigating 410 
causality of sequence variants in human disease. Nature. 2014 Apr 24;508(7497):469-76. 411 
9. van Rheenen W, Diekstra FP, van den Berg LH, Veldink JH. Are CHCHD10 412 
mutations indeed associated with familial amyotrophic lateral sclerosis? Brain. 2014 413 
Dec;137(Pt 12):e313. 414 
10. Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic 415 
variation in 60,706 humans. Nature. 2016 Aug 18;536(7616):285-91. 416 
11. Genome of the Netherlands C. Whole-genome sequence variation, population 417 
structure and demographic history of the Dutch population. Nat Genet. 2014 Aug;46(8):818-418 
25. 419 
12. Ait-El-Mkadem S, Chaussenot A, Bannwarth S, Rouzier C, Paquis-Flucklinger V. 420 
CHCHD10-Related Disorders. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, 421 
Amemiya A, Bean LJH, et al., editors. GeneReviews(R). Seattle (WA)2015. 422 
13. Raczy C, Petrovski R, Saunders CT, et al. Isaac: ultra-fast whole-genome secondary 423 
analysis on Illumina sequencing platforms. Bioinformatics. 2013 Aug 15;29(16):2041-3. 424 
14. Zheng X, Levine D, Shen J, Gogarten SM, Laurie C, Weir BS. A high-performance 425 
computing toolset for relatedness and principal component analysis of SNP data. 426 
Bioinformatics. 2012 Dec 15;28(24):3326-8. 427 
15. McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect Predictor. Genome 428 
Biol. 2016;17(1):122. 429 
16. Ionita-Laza I, Lee S, Makarov V, Buxbaum JD, Lin X. Sequence kernel association 430 
tests for the combined effect of rare and common variants. Am J Hum Genet. 2013 Jun 431 
6;92(6):841-53. 432 
17. Millecamps S, Salachas F, Cazeneuve C, et al. SOD1, ANG, VAPB, TARDBP, and 433 
FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J 434 
Med Genet. 2010 Aug;47(8):554-60. 435 
18. Kurzwelly D, Kruger S, Biskup S, Heneka MT. A distinct clinical phenotype in a 436 
German kindred with motor neuron disease carrying a CHCHD10 mutation. Brain. 2015 437 
Sep;138(Pt 9):e376. 438 
 22 
19. Wong CH, Topp S, Gkazi AS, et al. The CHCHD10 P34S variant is not associated 439 
with ALS in a UK cohort of familial and sporadic patients. Neurobiol Aging. 2015 440 
Oct;36(10):2908 e17-8. 441 
20. Abdelkarim S, Morgan S, Plagnol V, et al. CHCHD10 Pro34Ser is not a highly 442 
penetrant pathogenic variant for amyotrophic lateral sclerosis and frontotemporal dementia. 443 
Brain. 2016 Feb;139(Pt 2):e9. 444 
21. Marroquin N, Stranz S, Muller K, et al. Screening for CHCHD10 mutations in a large 445 
cohort of sporadic ALS patients: no evidence for pathogenicity of the p.P34S variant. Brain. 446 
2016 Feb;139(Pt 2):e8. 447 
22. Dobson-Stone C, Shaw AD, Hallupp M, et al. Is CHCHD10 Pro34Ser pathogenic for 448 
frontotemporal dementia and amyotrophic lateral sclerosis? Brain. 2015 Oct;138(Pt 10):e385. 449 
23. Genin EC, Plutino M, Bannwarth S, et al. CHCHD10 mutations promote loss of 450 
mitochondrial cristae junctions with impaired mitochondrial genome maintenance and 451 
inhibition of apoptosis. EMBO Mol Med. 2016 Jan;8(1):58-72. 452 
24. Zhang M, Xi Z, Zinman L, et al. Mutation analysis of CHCHD10 in different 453 
neurodegenerative diseases. Brain. 2015 Sep;138(Pt 9):e380. 454 
25. Chio A, Mora G, Sabatelli M, et al. CHCH10 mutations in an Italian cohort of 455 
familial and sporadic amyotrophic lateral sclerosis patients. Neurobiol Aging. 2015 456 
Apr;36(4):1767 e3-6. 457 
26. Dols-Icardo O, Nebot I, Gorostidi A, et al. Analysis of the CHCHD10 gene in patients 458 
with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. Brain. 2015 459 
Dec;138(Pt 12):e400. 460 
27. Teyssou E, Chartier L, Albert M, et al. Genetic analysis of CHCHD10 in French 461 
familial amyotrophic lateral sclerosis patients. Neurobiol Aging. 2016 Jun;42:218 e1-3. 462 
28. Zhou Q, Chen Y, Wei Q, et al. Mutation Screening of the CHCHD10 Gene in Chinese 463 
Patients with Amyotrophic Lateral Sclerosis. Mol Neurobiol. 2016 Apr 7. 464 
29. Auranen M, Ylikallio E, Shcherbii M, et al. CHCHD10 variant p.(Gly66Val) causes 465 
axonal Charcot-Marie-Tooth disease. Neurol Genet. 2015 Jun;1(1):e1. 466 
30. Pasanen P, Myllykangas L, Poyhonen M, et al. Intrafamilial clinical variability in 467 
individuals carrying the CHCHD10 mutation Gly66Val. Acta Neurol Scand. 2016 468 
May;133(5):361-6. 469 
31. Penttila S, Jokela M, Bouquin H, Saukkonen AM, Toivanen J, Udd B. Late onset 470 
spinal motor neuronopathy is caused by mutation in CHCHD10. Ann Neurol. 2015 471 
Jan;77(1):163-72. 472 
 473 
